More than 40 000 new HIV infections occur every year in the United States [1, 2] and the number of prevalent cases of HIV was >1.1 million in 2013 [3] . Meanwhile, the advent of effective combination antiretroviral therapy (ART) in 1996 extended life expectancy for a 20-year-old person with HIV from 39 years in 1996 to 73 years in 2011 [4, 5] . As people with HIV live longer, they appear to develop diseases and conditions that are characteristic of middle-aged and older populations, including rising obesity and weight gain [6] , diabetes, cardiovascular disease, and other chronic conditions [7] . Additionally, HIV and its treatment may themselves increase the prevalence of some conditions. Collectively, these noninfectious complications are referred to as HIV-associated non-AIDS (HANA) conditions [8] [9] [10] . HANA conditions have important implications for the complexity of providing quality clinical care given that such care often involves polypharmacy and multiple specialty providers. HANA conditions also have an economic impact, with the majority of the costs covered by Medicaid and Medicare [11] .
Understanding disease burden in HIV-infected persons in the United States, and how this burden is changing over time, is challenging. Pioneering efforts have been made in the Veterans Aging Cohort Study (VACS) [12, 13] , but there is little similar evidence from other nationally representative populations with large numbers of people living with HIV. Some efforts at the state level have helped our understanding of costs and care of individual conditions [14] [15] [16] , but few studies have conducted multistate analyses [17] [18] [19] [20] . One recent study examined trends in comorbidities for commercial, Medicaid, and Medicare enrollees with HIV, though the size and generalizability of the Medicaid population were limited [21] . No studies to our knowledge have been representative longitudinal studies, nor have any focused specifically on the Medicaid population.
Our objective was therefore to identify trends in HIV Medicaid enrollee characteristics and comorbidities over time.
The HIV Medicaid population is important because Medicaid is the largest source of insurance coverage among persons with HIV, covering >40% of all persons with HIV who receive regular care [11] . Medicaid also covers some of the most vulnerable patients in the United States, as Medicaid enrollees are all low-income and are disproportionately disabled [22] or from racial/ethnic minority groups [23] . This represents the first known large-scale effort to characterize Medicaid enrollees living with HIV and associated comorbidities.
METHODS
We used a retrospective study design using administrative claims data from 2001-2012 Medicaid Analytic eXtract (MAX) data from the 14 states with the highest HIV prevalence: New York, California, Florida, Texas, Maryland, New Jersey, Pennsylvania, Illinois, Georgia, North Carolina, Virginia, Louisiana, Ohio, and Massachusetts. These states accounted for about 75% of HIV prevalence in the United States in 2012 [24] . We obtained a 100% sample for each state.
Sample Selection
We first identified a sample of n = 85 389 808 Medicaid enrollees for the years 2001-2012 from the 14 states. Second, we identified an initial HIV sample of n = 615 281 individuals using ICD-9 codes (HIV disease code 042, asymptomatic HIV code V08) or an indicator of ever having received ART. Third, from the initial sample, we classified enrollees into "HIV likely" vs "HIV possible" (see the flowchart in the Supplementary Figure A1) . Those in the "HIV likely" category (n = 494 322) constituted our base cohort and included (1) those with ≥2 diagnostic codes for HIV or prescriptions for ≥2 antiretroviral medications (n = 448 284); (2) those with only 1 HIV diagnostic code from an inpatient or long-term care stay (n = 18 246); (3) those with only 1 diagnostic code for HIV but an additional diagnostic code for HIV wasting or HIV dementia (n = 6705); or (4) only 1 HIV diagnostic code but codes for ≥2 CD4 count tests (n = 21 087).
The base cohort of n = 494 322 individuals translated into a final analytic sample of n = 5 848 394 person-quarters. This sample excluded those not eligible for Medicaid for the full quarter (n = 1 920 742), those in comprehensive managed care in Massachusetts or Pennsylvania (n = 369 814) due to incomplete encounter data [25] , those age <18 years (n = 481 718) or >64 years (n = 562 305) in the quarter, those dually eligible for Medicaid and Medicare in the quarter (n = 492 124), and quarters where an individual had <12 months of Medicaid eligibility in the look-back period (n = 552 333). An additional n = 606 694 person-quarters from 2001-2002 were excluded from rate calculations, as these person-quarters lacked sufficient prior observation time, though these quarters were used in classifying enrollees as having comorbid conditions.
Measures
Our primary independent variable was an indicator for year. Our dependent variables included indicators for 10 of the most prevalent comorbid conditions observed in claims: cardiovascular disease, any pulmonary disorder, hypertension, diabetes, any liver disease, psychiatric disease, hyperlipidemia, anemia, renal insufficiency, and an indicator for having any HIV-related condition (see Supplementary Table A2 for detailed measure definitions). We also examined total number of comorbid conditions per enrollee out of 27 total comorbid conditions. To identify these comorbidities, we used the classification system developed by the VACS [26] . For each comorbid condition, we required 2 outpatient claims or 1 inpatient claim with evidence of the condition within the look-back period. The full list of conditions is presented in the Supplementary Data.
Analyses
The unit of observation was the person-quarter. In our primary analysis, to identify evidence of a comorbid condition, we used a rolling 2-year look-back period. For a patient eligible for the full quarter q, if the patient had evidence of a comorbid condition in quarter q or in the preceding 7 quarters, then the patient was classified as having that condition in quarter q.
We calculated descriptive statistics by year to assess the changing demographics of the HIV Medicaid population. To calculate trends in comorbidities over time, for the 10 most common comorbidities, we used logistic models to estimate unadjusted and adjusted changes in the odds of an enrollee having each condition. To calculate trends in the number of comorbid conditions over time, we used linear regression models. For all models, we treated year as an indicator variable. Our logistic models estimated the odds of an enrollee having a condition were excluded from outcome analyses to allow for a 2-year look-back period, though data from these years were used in determining whether an enrollee had a condition in 2003. Adjusted models included age, sex, race, disability status, managed care enrollment, and state. Both adjusted and unadjusted models accounted for months of eligibility in the look-back period. For all analyses, we used robust variance estimators with 99% confidence intervals. The significance level was set at P < .001.
Sensitivity Analyses
We conducted sensitivity analyses to ensure that results were robust. First, we estimated each outcome using an all-quarter look-back, where a patient eligible for the full quarter q was classified as having that condition in quarter q if the patient had claims evidence of a comorbid condition in quarter q or in any of the preceding quarters. Arguably, this all-quarter look-back method would more closely capture the concept of condition prevalence. Second, we repeated all analyses using a 1-year rolling look-back period. Third, we re-ran all primary analyses clustering errors at the state level in place of robust variance estimators. Finally, we re-ran our analyses examining changes in number of comorbid conditions using Poisson regression.
RESULTS

Trends in Population Demographics and Service Utilization
The characteristics of the HIV Medicaid population did not meaningfully change from 2003 to 2012 (Table 1) 
Trends in Comorbidities
When aggregating data from 2003 to 2012, hypertension was the most common comorbid condition (26.6%). This was followed by psychiatric disease (23.7%), any liver disease (22.6%), and pulmonary disorder (21.9%). At least 1 in 8 enrollees showed evidence of any HIV-related condition, cardiovascular disease, hyperlipidemia, and/or diabetes. Enrollees had a mean of 3.0 chronic conditions, and approximately 75% had evidence of at least 1 chronic condition. The full results are presented in the Supplementary Data.
Unadjusted changes over time for the 10 most common conditions are shown in Figure 1 . Nine of the 10 conditions increased over time, with only HIV-related conditions declining; though not among the top 10 conditions, rates of HIVrelated cancer also declined, whereas rates of all other cancer increased (Supplementary Data). As shown in Figure 2 , the percentage of enrollees exhibiting no evidence of any of the 27 measured comorbid conditions decreased from 29.2% in 2003 to 22.2% in 2012, whereas the percentage of enrollees exhibiting evidence of 5 or more conditions increased from 21.1% in 2003 to 27.4% in 2012-indicating that more than one-quarter of HIV Medicaid enrollees had 5 or more comorbid conditions by the end of the study period. 
Sensitivity Analyses
Results from all sensitivity analyses were directionally similar to our primary analyses. As anticipated, more conservative assumptions yielded smaller effect sizes, and less conservative assumptions yielded larger effect sizes. As shown in Table  2 (third set of columns), when using an all-quarter look-back period, rates for all conditions were higher in 2012 as compared with 2012 using the 2-year look-back period. For instance, the all-quarter look-back shows that about 40% of enrollees had evidence of hypertension or psychiatric disease by 2012, and about one-third had pulmonary disorder, liver disease, and/or cardiovascular disease by 2012. Adjusted regression estimates suggest that for half of the conditions examined, the odds of an enrollee having evidence of that condition more than doubled between 2003 and 2012. Additional sensitivity analyses are shown in the Supplementary Data. Although rates of comorbid conditions increased over time, the percentage of enrollees having any HIV-related condition declined; this was also true of HIV-related cancers. This is likely due to dramatic improvements in ART. The most consequential improvement was widespread implementation of 1-pill-oncea-day therapy, but there is also evidence that ART adherence improved over this time period [27] . As would be expected if virologic control improved, our data show that rates of HIV-related conditions fell, though rates of all HANA conditions increased.
The conditions with the largest unadjusted increases over time included hyperlipidemia, hypertension, and diabetes-chronic conditions associated with older age but not specifically associated with HIV [7, 28, 29] . Although these data do not imply that increased rates are caused by HIV or its treatments, they do suggest that these age-associated conditions may be increasing at faster rates in persons with HIV, when compared with the literature on trends in the general US population [30] [31] [32] .
Although anemia has historically been associated with HIV clinical disease progression, it is difficult to speculate on why rates of anemia are increasing given that these claims data do not include laboratory diagnoses. The etiology of anemia in HIV is clearly multifactorial [33] . One of the most intriguing hypotheses is that HIV, even when treated, is a proinflammatory state that looks a great deal like the anemia of inflammation often seen in aging populations that may be driven by factors such as abnormal cytokine production and disordered iron metabolism [34] . This is the first large, multistate longitudinal study of comorbid conditions in Medicaid enrollees with HIV that has documented changes in rates of comorbid conditions over a 10-year period, covering approximately 75% of HIV Medicaid patients in the United States. Only a few prior studies have examined changes over time in rates of comorbid conditions in persons with HIV, none of which have focused explicitly on the Medicaid population. Gallant et al. examined trends in comorbidities for commercial, Medicaid, and Medicare enrollees with HIV and found increases in comorbid conditions [21] . However, the Medicaid population examined was limited to 26 000 HIV-infected enrollees, and analyses did not account for critical Medicaid-specific factors, such as dual eligibility, managed care enrollment, or basis of eligibility. Erdem et al. examined Medicare Part A beneficiaries with HIV and found that chronic condition rates increased between 2008 and 2010 [35] . In an Italian HIV cohort that directly examined patients, rates of hypertension and diabetes increased between 2010 and 2014 [36] . A Swiss HIV cohort study analyzed rates of comorbid conditions in 2008 by direct examination, as well as rates of clinical events in the subsequent 3 years, but did not examine longitudinal changes [37] . A 2007 VACS study examined comorbidities in veterans with HIV [26] . However, differing demographics of veteran and Medicaid populations limit the value of direct comparisons, and we are not aware of data from the VACS cohort that describe changes in prevalence of comorbid conditions over time.
It is important to note that this is not a classic cohort study or a balanced panel because people entered and left the study sample every month as they gained and lost Medicaid coverage. However, all Medicaid enrollees that we studied were Medicaid eligible for at least 1 continuous year, and the average enrollee was eligible for nearly 75% of all months in the study period. Thus, our analysis has features of both a cohort study and a serial, cross-sectional analysis. The population examined is the complete 100% universe of Medicaid patients in 14 states over the 12-year period. Thus, changes in rates of comorbid conditions can be interpreted as a measure of the increased burden of illness that Medicaid providers are facing over that time, and not as a pure measure of epidemiologic trend or sample anomaly. Although we use a rolling 2-year look-back period to control for observation time bias when estimating time trends, our sensitivity analyses using an all-quarter look-back period may more accurately capture the concept of point-in-time disease prevalence, particularly for later years of the study period. These estimates suggest an even greater burden of disease in the HIV Medicaid population than observed in our primary analyses.
Our findings have 2 main implications for clinicians and policy-makers. First, because Medicaid patients with HIV are aging and accumulating comorbid conditions, their care is increasingly complex. Persons with HIV will gradually need primary care, HIV care, and other specialty care, which may involve coordination among multiple providers. Polypharmacy and its attendant challenges will also increase as enrollees take more medications for multiple conditions [38] . Thus, it is important for Medicaid providers and health plans to ensure access to high-quality coordinated care for this population while accounting for increasingly complex patient needs through appropriate disease management.
Second, notwithstanding ways in which effective ART, if used correctly, can prevent progression of HIV, the care of persons with HIV is likely to become costlier. These costs are disproportionately borne by the public sector. About 25% of persons with HIV have Medicare coverage, most of whom are dually eligible for Medicaid [39] , and about 40% have Medicaid coverage [11] . In 2011, per capita spending on HIV Medicaid enrollees was $26 807-approximately 5 times that of the average Medicaid enrollee [11] . Meanwhile, in recent years, Congress has been considering changes to the Affordable Care Act, including to the Medicaid program. As our findings show, persons with HIV are increasingly complex, and thus expensive, to care for. Legislation that reduces access to care for persons with HIV would have severely negative effects on HIV patients [40] . Our findings underline the importance of access to and affordability of care for persons with HIV, particularly given that not only HIV infection but also most of the comorbid conditions examined are highly treatable.
Limitations
This analysis has limitations. First, we were unable to estimate true disease prevalence given that we only observed what was present in claims; thus, we instead captured evidence of service utilization for comorbid conditions. We used rolling quarters to capture this service utilization, to minimize observation time bias, but this likely resulted in conservative estimates of true underlying prevalence. Second, claims data were limited in that they were used for billing purposes and lacked clinical indicators. This may have resulted in misclassification, which would have underestimated rates of comorbid conditions. This also means that we were unable to completely capture the etiology of disease and that some important conditions, such as nondementing cognitive decline, were not well captured in the data. Third, the results rely on reports from individual state Medicaid programs, which do not have consistent reporting and coding procedures. Although a claims aggregator was used to standardize data, there may have been state anomalies that affected aggregate rates even after adjusting for state. Fourth, we did not exclude patients in managed care plans because MAX files included reliable encounter data from health plans in most states [41] , except for Massachusetts and Pennsylvania, which were excluded. To account for reporting and population differences, we controlled for managed care in our models, though this may still have underestimated disease prevalence, particularly in later years when managed care participation is greater. Fifth, because we only observed patients enrolled in Medicaid, we did not have data on the date of first HIV diagnosis, which may predate enrollment in Medicaid; thus we could not account for duration of diagnosis. Finally, although the 14 states examined capture ~75% of HIV prevalence, the results may not be generalizable to all 50 states.
Conclusions
In conclusion, from 2001 to 2012, when there were dramatic improvements in ART and ART adherence, our data showed corresponding declines in rates of HIV-related conditions over this time period. However, notwithstanding these improvements in HIV patients' primary disease, there were substantial increases in rates of comorbid conditions. By 2012, rates of hypertension, psychiatric disease, liver disease, and pulmonary disorder were all >20%, and enrollees had about 3.1 comorbid conditions on average, with over a quarter of enrollees having 5 or more conditions. These findings have important implications for the complexity and costs of clinical care and for the state Medicaid programs serving these patients.
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